Pangali EV/EBITDA Thermo Fisher (TMO)

The strategic goal of Thermo Fisher Scientific (TMO) is to maintain its status as a defensive asset resilient to macro shocks. The business valuation via EV/EBITDA trends illustrates progress toward this goal, with the metric currently at 24.20. Growth is driven by a sales model based on consumables for high-end equipment and impeccable liquidity, creating insurmountable barriers for competitors in the medical diagnostics sector.

This metric compares the total enterprise value, including debt and taxes, with its operating profit before depreciation and amortization. This ratio reveals the actual value of the company by neutralizing distortions caused by excessive leverage. For Thermo Fisher Scientific (TMO), this is critical, as the outsourcing of logistics and services impacts the cost structure and debt load. Analyzing the EV/EBITDA multiple, accounting for net debt, allows for the timely identification of capital impairment risks.